Associated Papers
Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.
Koga T et al.
Cancer Science, 2022
34997674 (PubMed )
Supplement: CAS-113-815-s001.pdf
Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland.
Grosse A et al.
Diagnostic Pathology, 2019
Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer.
Romanidou O et al.
Therapeutic Advances in Medical Oncology, 2016
Mechanisms of resistance to EGFR tyrosine kinase inhibitors.
Huang L et al.
Acta Pharmaceutica Sinica. B, 2015
Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.
Stewart EL et al.
Translational Lung Cancer Research, 2015
Genetic and epigenetic changes in lung carcinoma and their clinical implications.
Wen J et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2011
EGFR mutations and the terminal respiratory unit.
Yatabe Y
Cancer Metastasis Reviews, 2010
Select a paper to view details